Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (DE:FLB)
FRANKFURT:FLB
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.11Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -7.07%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While the company showed strong financial discipline and growth in instrument sales, it faced notable revenue declines and challenges in the Americas academic market. Strategic initiatives in proteomics and partnerships offer promising future prospects but are yet to significantly offset current revenue challenges.Company Guidance
In the first quarter of 2025, Standard BioTools reported revenue of $40.8 million, a 10% decline year-over-year, but in line with expectations. Despite challenges, including a dynamic operating environment and pressures from tariffs and funding, the company maintained its full-year revenue guidance of $165 million to $175 million. The revenue mix comprised 35% consumables, 19% instruments, and 43% services, with instruments showing double-digit growth driven by demand for the Hyperion XTi spatial imaging systems. The company also reported a 22% year-over-year improvement in non-GAAP operating expenses, with adjusted EBITDA improving by 29%. With $261 million in cash and equivalents and no material debt, Standard BioTools remains focused on managing costs and driving operational efficiencies, with an eye on achieving adjusted EBITDA profitability by 2026.Positive Financial Improvements
Non-GAAP operating expenses decreased by 22% year-over-year, operating loss improved by 45%, and adjusted EBITDA improved by 29%. Cash burn reduced by 33% compared to the previous year.
Strategic Foothold in Proteomics
The company announced new SomaScan offerings and partnerships, particularly with Illumina, expanding their reach in clinical research. New product launches and strategic initiatives are driving interest and growth.
Strong Instrument Revenue Growth
Instrument revenue increased by 24% year-over-year, driven by demand for Hyperion XTi spatial imaging systems.
---
DE:FLB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:FLB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | €0.99 | €0.92 | -7.58% |
Feb 26, 2025 | €1.20 | €1.10 | -8.33% |
Oct 30, 2024 | €1.70 | €1.63 | -4.12% |
Jul 31, 2024 | €2.16 | €1.76 | -18.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Standard BioTools (DE:FLB) report earnings?
Standard BioTools (DE:FLB) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Standard BioTools (DE:FLB) earnings time?
Standard BioTools (DE:FLB) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Standard BioTools stock?
The P/E ratio of Standard BioTools is N/A.
What is DE:FLB EPS forecast?
DE:FLB EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.
---